# Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

> **NCT03209518** · — · COMPLETED · sponsor: **Takeda** · enrollment: 312 (actual)

## Conditions studied

- Premenopausal Breast Cancer

## Interventions

- **DRUG:** Leuprorelin acetate

## Key facts

- **NCT ID:** NCT03209518
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-18
- **Primary completion:** 2018-10-10
- **Final completion:** 2018-10-10
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03209518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03209518, "Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03209518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*